In 2017, Canada won the dispute against the US-based pharmaceutical company Eli Lilly in investor-state arbitration (ISA). Foreign investors can sue sovereign governments in ISA in case of mistreatment, such…
Tag: eli lilly
in Canada, European Union, Infringement, IP, Jurisdiction, Patentability, Patents, Pharmaceutical Drugs, Regulatory Policy, Supreme Court of Canada, UK, UK, US, US-Canada Relations0by Editor
629
Sitting This One Out: SCC Refuses to Clarify “Promise of a Patent” Doctrine
Last month, the Supreme Court of Canada (SCC) denied leave to appeal in the case Eli Lilly Canada Inc v Novopharm Ltd, passing on an opportunity to clarify the controversial…
in Copyright, Copyright Reform, European Union, IP, IP Reform, Patents, Pharmaceutical Drugs, Supreme Court of Canada, Trademarks, US, US-Canada Relations, WIPO0by Editor
464
A Cautionary Kudos: Canada Moves Up on USTR IP Watch List
Earlier this month, the United States Trade Representative (USTR) released its annual “Special 301 Report,” which evaluates the intellectual property rights (IPR) protection and enforcement of its trading partners. Over…
The Written Description Requirement as Interpreted in Ariad v. Eli Lilly
George Nathanael is a JD candidate at Osgoode Hall Law School and is taking the Patent Law course. Earlier this week the U.S. Court of Appeals for the Federal Circuit…